LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Vivian Cervantes - Investor Relations, Gilmartin Group John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Lily Lozada - JPMorgan Kallum Titchmarsh - Morgan Stanley Richard Newitter - Truist Securities Danielle Antalffy - UBS Ben Haynor - Lake Street Capital Markets Operator Welcome to the Treace Medical Concepts Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.10 per share a year ago.
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESS Newswire / February 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.